PULM.US Pulmatrix Inc

Healthcare Pharmaceuticals USA Stocks
1.33 USD
Close of Nov 17, 2026
1.06 4.94
Market cap
USD 4.84M
P/E
-
P/B
2.98x
ROE
-341.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PULM.US undervalued?

Graham number

The Graham number of Pulmatrix Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pulmatrix Inc fundamental analysis

No fundamental analysis for Pulmatrix Inc yet.

Pulmatrix Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pulmatrix Inc

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed …

Full company profile